title: Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma.
abstract: To assess the prognostic value and clinicopathological correlate of the expression of topoisomerase II alpha, ki67, and p53 in non muscle-invasive urothelial bladder carcinoma. Seventy one cases of formalin-fixed, paraffin-embedded bladder biopsy specimens diagnosed as non muscle invasive urothelial carcinoma were processed by searching our surgical pathology files from 2001-2003. The patients were followed-up for 3-77 months (median = 28). In each case, one tissue block was chosen for immunohistochemical expression of ki67, topoisomerase II alpha and p53. This expression was associated with the pathological stage, grade, recurrence, progression and survival. Positive staining of topoisomerase II alpha, ki67, and p53 was found respectively in 39.5, 38, and 38% cases. We have found a statistically significant correlation between the expression of each of the 3 markers and WHO grade and recurrence. The surexpression of topoisomerase II alpha was associated within increased tumor stage. p53 was associated with tumor progression. On multivariate analysis, p53 was an independent factor of progression into muscle-invasive tumors and none of these markers had predictive value on recurrence. The present findings support the clinical relevance of these markers in bladder cancer.
authors.affiliation: a Department of Pathology , Farhat Hached University Hospital , Sousse , Tunisia.
authors.forename: Soumaya
authors.initials: S
authors.lastname: Ben Abdelkrim
authors.forename: Soumaya
authors.initials: S
authors.lastname: Rammeh
authors.forename: Sonia
authors.initials: S
authors.lastname: Ziadi
authors.forename: Taghrid
authors.initials: T
authors.lastname: Tlili
authors.forename: Mahdi
authors.initials: M
authors.lastname: Jaidane
authors.forename: Moncef
authors.initials: M
authors.lastname: Mokni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000378:metabolism*
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D019394:Ki-67 Antigen; D016159:Tumor Suppressor Protein p53; D004250:DNA Topoisomerases, Type II
keywords: bladder cancer; immunohistochemistry; ki67; p53; prognosis; topoisomerase II alpha